Linsitinib

Chemical Compound
Identifiers
CAS Number
PubChem CID
ChemSpider ID
UNII
ChEBI
ChEMBL
Properties
Chemical Formula
Molar Mass
Appearance
Density
Melting Point
Boiling Point
Hazards
GHS Pictograms	[[File:|50px]]
GHS Signal Word
GHS Hazard Statements
NFPA 704	[[File:|50px]]
References

Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R).<ref>,

 Discovery of OSI-906: A selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor, 
 Future Medicinal Chemistry, 
 2009,
 Vol. 1(Issue: 6),
 pp. 1153–71,
 DOI: 10.4155/fmc.09.89,
 PMID: 21425998,</ref>  This prevents tumor cell proliferation and induces tumor cell apoptosis.<ref>

Linsitinib(link). {{{website}}}. National Cancer Institute.

</ref>

Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012.<ref name="springer.com">

Linsitinib - AdisInsight(link). adisinsight.springer.com.

</ref>

Phase II clinical trials were initiated for multiple myeloma, ovarian cancer, hepatocellular carcinoma, and NSCLC, but subsatisfactory results caused research for these indications to be discontinued.<ref name="springer.com"/> A phase III clinical trial found that linsitinib did not increase survival in patients with adrenocortical carcinoma.<ref>,

 Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study, 
 The Lancet Oncology, 
 
 Vol. 16(Issue: 4),
 pp. 426–435,
 DOI: 10.1016/S1470-2045(15)70081-1,
 PMID: 25795408,
 
 
 Full text,</ref> As of 2017, no clinical trials were in progress.<ref name="springer.com"/>

References

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia